The PD-L1/PD-1 pathway has showed a remarkable value among all immune checkpointsbecause promising and impressing responses in many tumors, such as melanoma,non-small-cell lung cancer (NSCLC) and renal cell carcinoma, were achieved intherapies targeting the PD-1/PD-L1 pathway [33]. This evidence concerns the gene CD274 and renal cell carcinoma.